Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

News & Analysis

China biotech company and industry news and analysis...

3SBio Has China Rights to Five Numab I-O Therapies following $15.2 Million Investment

AstraZeneca's Imfinzi, a PD-L1 Immunotherapy, Approved in China for NSCLC

Alphamab Oncology Closes $234 Million Hong Kong IPO; Climbs 35% in First Session

Ascentage Reports 95% Complete Response of BCR-ABL Inhibitor in Leukemia Patients

JOINN Bio Raises $60 Million for US-China Biologic CDMO Operations

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China